NPCEHealthcare · Medical DevicesThe 9 Wall Street analysts covering NeuroPace, Inc. hold a median 12-month price target of $20 — +42.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NeuroPace, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (81): The business earns solid, repeatable profits on what it owns.
Volatility (43): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NPCE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +42.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 July 2026 | Mizuho | Initiates | Outperform | $22 |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | $19 → $20 |
| 27 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Dec 2025 | UBS | Maintains | Buy | — |
| 10 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 13 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
| 28 May 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 May 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 May 2025 | JP Morgan | Maintains | Overweight | — |
| 14 Apr 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Mar 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 30 Jan 2025 | Wells Fargo | Maintains | Overweight | — |
| 21 Jan 2025 | UBS | Initiates | Buy | — |
| 17 Dec 2024 | JP Morgan | Maintains | Overweight | — |
| 13 Nov 2024 | Wells Fargo | Maintains | Overweight | — |
| 14 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NPCE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 28% of US stocks
Cheaper than 3% of US stocks
Cheaper than 93% of US stocks
Higher than 66% of US stocks
Higher than 33% of US stocks
Higher than 92% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Higher than 13% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeuroPace, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeuroPace's IGE expansion is facing a regulatory delay, with the company working through the FDA review process. Attention is shifting to rising adoption of its RNS technology in the meantime.
Why it matters — A delay in the IGE expansion affects a key growth avenue for NeuroPace, so investors following NPCE would track how the FDA review progresses and how RNS adoption performs.
Zacks noted that NeuroPace's stronger RNS adoption, narrowing losses, and AI expansion support growth, but also cited its premium valuation, liquidity concerns, and regulatory risks. The report weighed these supportive factors against the risks facing the company.
Why it matters — A NeuroPace watcher would care because the report highlights both the growth drivers behind the company's improving performance and the valuation, liquidity, and regulatory factors that could shape its outlook.
NeuroPace shares have fallen 12.7% over three months, with the pullback raising questions about whether it presents a buying opportunity. The company's stronger RNS growth, raised 2026 guidance, and AI expansion are weighed against a less certain regulatory path for IGE after an FDA setback.
Why it matters — A NPCE watcher would care because the report highlights both the company's growth momentum and the regulatory uncertainty affecting its IGE pathway.
NeuroPace held its Q2 2026 earnings conference call, with management discussing the company's quarterly financial results and operational performance.
Why it matters — NPCE watchers would care because the earnings call provides direct insight into the company's financial health, business execution, and management's outlook.
NeuroPace reported Q2 revenues up 17.1% as demand for its RNS technology strengthened, delivering earnings that beat estimates. The company also reported a narrower loss and raised its 2026 revenue outlook.
Why it matters — The stronger-than-expected results and raised 2026 revenue outlook signal continued momentum for NeuroPace's RNS business, which NPCE watchers will track for growth trajectory.
The 9 Wall Street analysts covering NeuroPace, Inc. have a median 12-month price target of $20, with estimates ranging from $18 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering NeuroPace, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeuroPace, Inc. 90 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, NeuroPace, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (81 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +42.6% from the last close, and Ticker Nerd's factor model ranks NeuroPace, Inc. 90 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeuroPace, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NPCE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $22 over the next 12 months.
NeuroPace, Inc. returned +62.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
NeuroPace Inc. is a medical technology company specializing in the development of innovative neurostimulation solutions for neurological disorders.
The most recent item we track (Zacks Investment Research, 17 Aug 2026): "NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth". NeuroPace's IGE expansion is facing a regulatory delay, with the company working through the FDA review process. Attention is shifting to rising adoption of its RNS technology in the meantime.
NeuroPace Inc. is a medical technology company specializing in the development of innovative neurostimulation solutions for neurological disorders. The company is primarily known for its RNS System, a groundbreaking implantable device designed to reduce the frequency and severity of epileptic seizures. The system continuously monitors brain activity and delivers targeted electrical stimulation to help normalize disruptive brainwave patterns. This technology serves as a critical option for patients with refractory epilepsy who do not respond to traditional medication treatment. NeuroPace’s approach directly impacts the healthcare sector, especially the neurology and medical devices markets, by providing a novel alternative to managing severe neurological conditions. Its contributions emphasize advancements in patient-tailored therapy solutions and underscore the growing role of precision medicine in healthcare. Founded with the mission to transform epilepsy treatment, NeuroPace Inc. embodies the synergy of cutting-edge science and patient care, positioning itself as an influential player in the medical technology industry.
CEO Mr. Joel D. Becker · 220 employees · United States · https://www.neuropace.com